Pure Global
NCT06368921

A Study of Recombinant Oncolytic Virus M1(VRT106) in Patients With Solid Tumors

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Biodistribution Characteristics, Biological Effects and Initial Efficacy of Recombinant Oncolytic Virus M1 for Injection (VRT106) in the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors
Guangzhou Virotech Pharmaceutical Co., Ltd.·Phase 1·ClinicalTrials.gov·biologicalRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Solid Tumor
Drug/Device/Intervention
VRT106
Study type
Interventional
Intervention type
biological
Sponsor & location
Primary sponsor
Guangzhou Virotech Pharmaceutical Co., Ltd.
Location
Guangzhou, China
Timeline & enrollment
Phase
Phase 1
Start date
Apr 01, 2024
End date
Dec 01, 2025
Enrollment
30 participants
Primary outcome

Evaluate the safety and tolerability of escalating doses of intratumoral injection of VRT106.,Characterize the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) levels.

Summary

To Evaluate the safety and tolerability of single and multiple intratumoral injections of
 recombinant oncolytic virus M1 (VRT106) in patients with locally advanced/metastatic solid
 tumors.

ICD-10 classifications
Malignant neoplasm: Connective and soft tissue, unspecifiedCarcinoma in situ, unspecifiedMalignant neoplasm: ParametriumMalignant neoplasm of other connective and soft tissueMalignant neoplasm: Lip, unspecified, inner aspect
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06368921
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06368921 through Pure Global AI's free database. This Phase 1 trial is sponsored by Guangzhou Virotech Pharmaceutical Co., Ltd. and is currently Recruiting. The study focuses on Solid Tumor. Target enrollment is 30 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.